Home / Stock ratings / BSX
Stock rating · Surgical & Medical Instruments & Apparatus
Boston Scientific Corp. (BSX) Stock Rating & Analysis
As of October 6, 2026, MELANY rates Boston Scientific Corp. 66 out of 100 (Favorable). Its highest factor score is catalyst setup at 89, and its lowest is price momentum at 12.
MELANY ratingRated 2026-10-06BSX · composite score
About Boston Scientific Corp.
Boston Scientific makes less invasive medical devices inserted into the body through small openings or cuts, with products for angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal diagnostics, interventional oncology, neuromodulation for chronic pain, and incontinence treatment. It markets to healthcare professionals and institutions globally, with foreign sales making up roughly 36% of total sales.
Rating as of 2026-10-06 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why BSX scores 66/100
BSX's 8 factor scores run from 12 to 89, and 6 of them sit above its composite of 66. Here is how BSX breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- P/E 17.1x vs sector 22.0x median
- PEG ratio 0.59 (< 1 = undervalued)
Margins, returns on capital, and balance-sheet strength.
- Gross margin 69%
Direction and relative strength of the recent share-price trend.
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Earnings in 22 days (strong beat history)
What Wall Street price targets and revisions are signalling.
- Analyst targets 43% upside
Near-term events that could move the stock.
- Earnings in 22 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How BSX compares
As of October 6, 2026, Boston Scientific Corp. is tied for 3rd of the 8 companies with a MELANY rating page in its SEC industry group (Surgical & Medical Instruments & Apparatus), where the average score is 66.
Key risks for BSX
- Weak price momentum, trend not yet confirmed, may need more time to set up
Sector and theme context
Boston Scientific Corp. sits in the Healthcare sector theme, which MELANY currently rates 37/100 for strength. Theme strength feeds BSX's momentum and catalyst factors above.
BSX trade plan (Pro)
MELANY has a full position plan for Boston Scientific Corp.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates BSX
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Boston Scientific Corp.'s 66/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about BSX
Is Boston Scientific Corp. (BSX) a buy?
As of 2026-10-06, MELANY rated Boston Scientific Corp. Favorable with a composite score of 66/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Boston Scientific Corp.'s MELANY score?
Boston Scientific Corp. (BSX) has a MELANY composite score of 66/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the BSX stock rating calculated?
MELANY scores BSX from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Boston Scientific Corp. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Boston Scientific Corp. (BSX) Favorable with a composite of 66/100 as of 2026-10-06. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the BSX stock price forecast?
MELANY does not publish price targets or forecasts for BSX. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 66/100 across eight factors for Boston Scientific Corp., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is BSX stock overvalued or undervalued?
MELANY's valuation factor currently reads 71/100 for Boston Scientific Corp., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives BSX's read.
What price should I buy BSX at?
Rather than chasing the current price, MELANY computes a smart entry zone for BSX: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying BSX stock?
The top risks MELANY currently flags for Boston Scientific Corp.: Weak price momentum, trend not yet confirmed, may need more time to set up. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Boston Scientific Corp. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 73/100 for Boston Scientific Corp., and earnings track record, at 75/100. The 66/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will BSX stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 12/100 for BSX right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this BSX rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-06. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores BSX continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, BSX included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.